Tests a glucose sensor app and coaching for pregnant adults with type 2 diabetes
Tests a glucose sensor app with coaching in pregnant adults with type 2 diabetes.
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
- Status
- Recruiting
- People taking part
- 124 people, planned
- Started
- 11 Jul 2024
- Expected to end
- Mar 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DEXCOM G7 PRO Continuous Glucose Monitor
- Patient mHealth app linked to a provider dashboard
- Care team coaching for medical and social needs (HUB)
- Provider dashboard
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women aged 18 or older who have type 2 diabetes from before pregnancy and a high A1c at enrolment. It tests an app with a glucose sensor and coaching against standard care.
- Age
- 18 years or older
- Sex
- Female only (pregnant individuals)
- Disease stage
- Up to 20 weeks of pregnancy (less than 20+6 weeks). Type 2 diabetes diagnosed before pregnancy, with A1c of 6.5% (48 mmol/mol) or higher at enrolment.
- Biomarker or test result
- A1c of 6.5% (48 mmol/mol) or higher at the time of enrolment
Main reasons for not taking part
- Not on Medicaid insurance
- Does not speak English or Spanish
- No smartphone with internet access
- Not able to complete the study requirements
- Does not consent to all study activities
This trial only enrols pregnant participants. The registry sentence this rests on: pregnant individuals age ≥18 years;
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- pregnant individuals age ≥18 years
- ≤20 weeks of gestation (specifically, <20+6 weeks)
- diagnosis of pregestational T2D and A1c ≥6.5% at the time of study enrollment
- Medicaid insurance
- English or Spanish speaking
- cognitively able to complete the study requirements
- consent to all study activities
- accessible for participation in study activities
- use a smartphone with internet access; Participants must also consent to the study team abstracting information from their electronic health records (EHRs), using CGM for glucose monitoring if randomized to the intervention group, tracking the participants' clinic, hospital, and emergency room visits during the study period, as well as tracking the number of times the participants use the ACHIEVE mobile health (mHealth) application (app), including what activities are used in the mobile application (e.g., recording blood glucose, scheduling appointments, messaging their healthcare providers, accessing educational resources)
Where in United States
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United StatesContact: Kartik Venkatesh, MD, PhDTaking people
About the trial
What the trial wants to find out
The ACHIEVE RCT will measure the effect of the intervention (mHealth app with CGM, provider dashboard, and care team coaching) compared to current standard care (prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist) on achieving glycemic control (hemoglobin A1c <6.5% in the third trimester). We hypothesize a 25% absolute increase in the proportion of participants in the intervention group who will meet the target hemoglobin A1c <6.5% in the third trimester compared to the standard care group
The 2 groups in the trial
- ACHIEVE InterventionExisting treatment, for comparison
The intervention includes a multi-component, including a mobile health (mHealth) application (app), provider dashboard, DEXCOM continuous glucose monitoring (CGM), and care team coaching for medical and social needs. The intervention group will also receive standard of care as described below.
Treatment: DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), and Provider dashboard
- Standard of careNo study treatment, for comparison
Standard of care includes prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist support.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ACHIEVE: Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
- Plain-language title
- Tests a glucose sensor app and coaching for pregnant adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 29 June 2026